Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report)’s share price traded down 1.6% during trading on Tuesday . The company traded as low as $5.00 and last traded at $5.00. 150 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 98,649 shares. The stock had previously closed at $5.08.
Innovent Biologics Stock Down 8.6 %
The stock has a 50 day simple moving average of $5.66 and a 200 day simple moving average of $5.18.
Innovent Biologics Company Profile
Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.
Further Reading
- Five stocks we like better than Innovent Biologics
- What Are Growth Stocks and Investing in Them
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Consumer Discretionary Stocks Explained
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
